Mn Services Vermogensbeheer B.V. Buys 900 Shares of Amgen Inc. (NASDAQ:AMGN)

Mn Services Vermogensbeheer B.V. raised its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 1.0% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 95,392 shares of the medical research company's stock after buying an additional 900 shares during the quarter. Mn Services Vermogensbeheer B.V.'s holdings in Amgen were worth $29,719,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in AMGN. HT Partners LLC acquired a new position in Amgen during the 1st quarter valued at $214,000. Morton Capital Management LLC CA increased its holdings in shares of Amgen by 10.2% during the 1st quarter. Morton Capital Management LLC CA now owns 6,478 shares of the medical research company's stock worth $2,018,000 after purchasing an additional 598 shares during the period. Optas LLC raised its position in shares of Amgen by 15.3% during the first quarter. Optas LLC now owns 1,361 shares of the medical research company's stock valued at $424,000 after buying an additional 181 shares during the last quarter. Brighton Jones LLC lifted its stake in shares of Amgen by 5.6% in the first quarter. Brighton Jones LLC now owns 29,000 shares of the medical research company's stock valued at $9,035,000 after buying an additional 1,532 shares during the period. Finally, MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH increased its stake in Amgen by 5,580.2% during the first quarter. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH now owns 41,238 shares of the medical research company's stock valued at $12,848,000 after acquiring an additional 40,512 shares during the period. Institutional investors and hedge funds own 76.50% of the company's stock.

Insider Activity at Amgen

In other Amgen news, SVP Rachna Khosla sold 1,500 shares of the business's stock in a transaction dated Thursday, June 5th. The stock was sold at an average price of $289.68, for a total transaction of $434,520.00. Following the completion of the sale, the senior vice president now directly owns 8,162 shares of the company's stock, valued at approximately $2,364,368.16. The trade was a 15.52% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.76% of the stock is owned by company insiders.

Amgen Price Performance

Shares of AMGN traded down $2.07 during mid-day trading on Friday, hitting $295.22. 2,191,182 shares of the company traded hands, compared to its average volume of 2,820,660. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62. The stock has a market capitalization of $158.74 billion, a price-to-earnings ratio of 39.10, a PEG ratio of 2.63 and a beta of 0.51. The business has a 50-day moving average of $281.33 and a 200 day moving average of $285.62. Amgen Inc. has a one year low of $253.30 and a one year high of $346.85.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical research company reported $4.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.18 by $0.72. The firm had revenue of $8.15 billion for the quarter, compared to the consensus estimate of $8.05 billion. Amgen had a return on equity of 176.32% and a net margin of 12.24%. The business's revenue for the quarter was up 9.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.96 EPS. As a group, equities analysts expect that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently weighed in on the company. Royal Bank of Canada decreased their price objective on Amgen from $324.00 to $320.00 and set an "outperform" rating on the stock in a report on Friday, May 2nd. Bank of America lifted their price target on shares of Amgen from $275.00 to $294.00 and gave the stock an "underperform" rating in a research note on Wednesday, March 5th. Erste Group Bank cut shares of Amgen from a "strong-buy" rating to a "hold" rating in a research note on Thursday, May 8th. Mizuho lifted their target price on shares of Amgen from $235.00 to $280.00 and gave the company a "neutral" rating in a research report on Wednesday, May 7th. Finally, Cantor Fitzgerald assumed coverage on shares of Amgen in a research report on Tuesday, April 22nd. They issued a "neutral" rating and a $305.00 price target for the company. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $309.22.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.